| Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study 2013 · Palmitoylethanolamide phase (crossover) · Adults with ocular hypertension who had not previously received treatment | 600 mg | 90 days | 40 |
| Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram 2020 · Group A and Group B, during their PEA treatment period · Adults aged 18 years or older with primary open-angle glaucoma or normal-tension glaucoma | 600 mg | 120 days | 40 |
| A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain 2022 · Active treatment group · Men and women aged 32–75 with type 1 or type 2 diabetes and diabetic-related peripheral neuropathy with neuropathic pain | 600 mg | 8 weeks | 33 |
| Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial 2022 · palmitoylethanolamide group · Patients in the acute phase of mania; age and sex not stated | 1.2 g | 6 weeks | 32 |
| Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial 2022 · PEA group · Patients with schizophrenia receiving stable-dose risperidone; age and sex not specified | 1.2 g | 8 weeks | 25 |
| The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial 2022 · PEA · Healthy adult volunteers aged 18 years or older, women and men, with no pain-related diagnosis | 1.2 g | 4 weeks | 14 |
| Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up 2014 · group A (PEA treatment) · Adults with normal-tension glaucoma; age and sex not reported | 600 mg | 26 weeks | — |
| Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial 2018 · Palmitoylethanolamide group · Patients with DSM-5 major depressive disorder and HAM-D score ≥19; predominantly male | 1.2 g | 6 weeks | — |
| Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study 2018 · ultramicronized palmitoylethanolamide group · Patients with carpal tunnel syndrome awaiting surgery, with sleep disorders and painful symptoms; age and sex not specified | 1.2 g | — | — |
| Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial 2019 · ultramicronized palmitoylethanolamide group · Adults with burning mouth syndrome and burning mouth intensity greater than 4 on the Numeric Rating Scale | 1.2 g | 60 days | — |
| A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis 2019 · 300 mg PEA group · Adults with mild to moderate knee osteoarthritis; age range and sex not specified | 300 mg | 8 weeks | — |
| A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis 2019 · 600 mg PEA group · Adults with mild to moderate knee osteoarthritis; age range and sex not specified | 600 mg | 8 weeks | — |
| The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial 2023 · Levagen+ (PEA) group · Adults aged 18–65 years without a stated illness, recruited as otherwise healthy adults | 600 mg | 12 weeks | — |
| Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial 2022 · Intervention group · Adults aged 18–80 with post-COVID-19 anosmia or hyposmia persisting at least 180 days | 700 mg | 90 days | 130 |
| Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea 2015 · PEA-transpolydatin group · Adolescents and young women aged 16–24 years with primary dysmenorrhea | 400 mg | 10 days | 110 |
| Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial 2023 · Combined therapy (um-PEA–LUT: once daily + olfactory training) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19 | 700 mg | 90 days | 76 |
| Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study 2023 · Group 2 · Adults with fibromyalgia | 1.2 g | 12 weeks | 62 |
| Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial 2023 · um-PEA–LUT alone (once daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19 | 700 mg | 90 days | 48 |
| Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study 2022 · Training-Naïve 1 (PEA-LUT plus olfactory training) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection, without prior olfactory training | 700 mg | 90 days | 43 |
| Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial 2023 · um-PEA–LUT alone (twice daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19 | 1.4 g | 90 days | 40 |
| A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients 2023 · Group B: Standard Therapy + PeaNoc XL · Adults aged 18–60, any sex, with arthritis and DAS 28 score ≥3.2, experiencing joint pain and inflammation | 400 mg | 12 weeks | 35 |
| Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study 2011 · Group A · Women with chronic pelvic pain related to endometriosis after laparoscopic conservative surgery | 800 mg | 90 days | 21 |
| The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)-Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results 2025 · food supplement (FS) · Adults aged 18–80, women and men, with metabolic syndrome; mean age 65 ± 10 years | 720 mg | 8 weeks | 19 |
| Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study 2022 · Training-Naïve 2 (PEA-LUT alone) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection, without prior olfactory training | 700 mg | 90 days | 16 |
| Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study 2022 · Previously trained group (PEA-LUT plus olfactory training) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection who had previously undergone olfactory training | 700 mg | 90 days | 10 |
| Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy 2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years | 600 mg | 26 weeks | 36 |
| Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial 2024 · PEA group · Healthy male and female university students aged 18 years and older | 600 mg | 6 weeks | 39 |
| Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial 2022 · LEV · Unvaccinated, nonhospitalized adults aged 19–53 recently diagnosed with COVID-19 | 1.2 g | 4 weeks | 30 |
| Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial 2011 · oral PEA · Patients with primary open-angle glaucoma or ocular hypertension, treated with timolol 0.5%, with intraocular pressure between 19 and 24 mm Hg; age and sex not reported | 600 mg | 60 days | — |
| Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome 2023 · PEA-LUT · Adults with fatigue and/or cognitive difficulties after mild COVID-19; age range not reported | 1.4 g | 8 weeks | 17 |
| Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome 2017 · palmitoylethanolamide/polydatin · Adults with irritable bowel syndrome; age and sex not stated | 400 mg | 12 weeks | — |